Atossa Therapeutics (ATOS, Financial) has successfully obtained a new patent from the United States Patent and Trademark Office, enhancing its intellectual property rights around (Z)-endoxifen formulations. This patent specifically focuses on enteric oral formulations of (Z)-endoxifen and its salts, which are used in the treatment of hormone-dependent breast and reproductive tract disorders.
The new patent underscores Atossa's commitment to advancing its proprietary (Z)-endoxifen formulations, enriching their portfolio with innovative compositions and therapeutic methods. (Z)-endoxifen is recognized for its role as a potent Selective Estrogen Receptor Modulator, which is a vital component in managing certain medical conditions linked to hormones.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Atossa Therapeutics Inc (ATOS, Financial) is $6.00 with a high estimate of $7.00 and a low estimate of $4.00. The average target implies an upside of 842.51% from the current price of $0.64. More detailed estimate data can be found on the Atossa Therapeutics Inc (ATOS) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Atossa Therapeutics Inc's (ATOS, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
